Autolus Therapeutics plc ADR (NASDAQ: AUTL) Stock In Prove Me State

Autolus Therapeutics plc ADR (AUTL) concluded trading on Thursday at a closing price of $1.35, with 5.46 million shares of worth about $7.37 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -59.58% during that period and on May 08, 2025 the price saw a gain of about 9.76%. Currently the company’s common shares owned by public are about 266.13M shares, out of which, 240.32M shares are available for trading.

Stock saw a price change of 0.00% in past 5 days and over the past one month there was a price change of 14.41%. Year-to-date (YTD), AUTL shares are showing a performance of -42.55% which decreased to -66.91% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.11 but also hit the highest price of $5.00 during that period. The average intraday trading volume for Autolus Therapeutics plc ADR shares is 1.70 million. The stock is currently trading -0.74% below its 20-day simple moving average (SMA20), while that difference is down -13.78% for SMA50 and it goes to -52.64% lower than SMA200.

Autolus Therapeutics plc ADR (NASDAQ: AUTL) currently have 266.13M outstanding shares and institutions hold larger chunk of about 53.88% of that.

The stock has a current market capitalization of $359.26M and its 3Y-monthly beta is at 1.69. It has posted earnings per share of -$0.87 in the same period. It has Quick Ratio of 10.77 while making debt-to-equity ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AUTL, volatility over the week remained 9.62% while standing at 11.13% over the month.

Stock’s fiscal year EPS is expected to drop by -4.27% while it is estimated to increase by 20.27% in next year. EPS is likely to grow at an annualized rate of 21.60% for next 5-years, compared to annual growth of 21.36% made by the stock over the past 5-years.

Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Goldman on November 18, 2024 offering a Buy rating for the stock and assigned a target price range of between $7 and $7.60 to it. Coverage by Redburn Atlantic stated Autolus Therapeutics plc ADR (AUTL) stock as a Buy in their note to investors on November 15, 2024, suggesting a price target of $13 for the stock. On November 09, 2023, Deutsche Bank Initiated their recommendations, while on March 27, 2023, Wells Fargo Resumed their ratings for the stock with a price target of $8. Stock get a Buy rating from Bryan Garnier on March 17, 2023.

Related Posts

Life Telegraph
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.